10 Best Dow Dividend Stocks To Watch For 2015: Momenta Pharmaceuticals Inc.(MNTA)
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the characterization and process engineering of complex molecules. These complex molecules include proteins; polypeptides; and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development and commercialization of generic versions of complex drug products, as well as for the discovery and development of novel drugs. It offers Enoxaparin sodium injection, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes. The company?s products also include M356, an abbreviated new drug application under FDA review, is a generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, which completed a Phase IIa clinical trial as an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate that is in preclinical development as a potential anti-cancer agent. It has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize Enoxaparin sodium injection. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Advisors' Opinion:- [By James Brumley]
Just bear in mind this is largely an all-or-nothing bet on the drug, though PRAN stock could rally nicely leading up to its D-Day approval.
Momenta Pharmaceuticals (MNTA)Like Sagent Pharmaceuticals, Momenta Pharmaceuticals (MNTA) is a generic drugmaker. And also like Sagent, priced at $16.14 per share, MNTA stock is easily put into the cheap stocks category.
- [By Dan Caplinger]
Lately, the stock market has turned on every word! from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more encouraging assessment of how long interest rates might remain low in order to stimulate and sustain economic growth, stocks climbed sharply, with the Dow posting triple-digit gains. Yet for MannKind (NASDAQ: MNKD ) , Momenta Pharmaceuticals (NASDAQ: MNTA ) , and Idera Pharmaceuticals (NASDAQ: IDRA ) , the news today was far from good, as all three stocks suffered declines of 10% or more.
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/10-best-dow-dividend-stocks-to-watch-for-2015-2.html
No comments:
Post a Comment